Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2019

Open Access 01-12-2019 | Metastasis | Case report

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report

Authors: Morgane Broudic-Guibert, Jean-Yves Blay, Léa Vazquez, Alexandre Evrard, Marie Karanian, Sophie Taïeb, Natalie Hoog-Labouret, Céline Mahier Ait Oukhatar, Rania Boustany-Grenier, Antoine Arnaud

Published in: Journal of Medical Case Reports | Issue 1/2019

Login to get access

Abstract

Background

Ameloblastomas are uncommon locally aggressive tumors of odontogenic epithelium that rarely metastasize. Currently, there is no standard of care for the metastatic forms. Several studies have shown that ameloblastomas frequently have a BRAF mutation.

Case presentation

We report a case of a 33-year-old Caucasian woman with ameloblastoma diagnosed 30 years ago who developed lung metastasis 19 years ago. Systemic oral treatment with vemurafenib, a BRAF inhibitor, was initiated 28 months ago within the AcSé French basket clinical trial of vemurafenib.

Conclusions

The patient has shown a durable clinical, functional, and radiographic partial response with vemurafenib. These observations suggest the possibility of introducing neoadjuvant and/or adjuvant targeted therapy in locally advanced ameloblastoma to improve outcome. BRAF inhibition has proved to be an efficient strategy in patients with a BRAF-mutated ameloblastoma.
Literature
Metadata
Title
Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
Authors
Morgane Broudic-Guibert
Jean-Yves Blay
Léa Vazquez
Alexandre Evrard
Marie Karanian
Sophie Taïeb
Natalie Hoog-Labouret
Céline Mahier Ait Oukhatar
Rania Boustany-Grenier
Antoine Arnaud
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2019
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-019-2140-6

Other articles of this Issue 1/2019

Journal of Medical Case Reports 1/2019 Go to the issue